BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16028441)

  • 1. Mucin-producing cholangiocarcinoma: clinical experience of 24 cases in 16 years.
    Kuo CM; Changchien CS; Wu KL; Chuah SK; Chiu KW; Chiu YC; Chou YP; Kuo CH
    Scand J Gastroenterol; 2005 Apr; 40(4):455-9. PubMed ID: 16028441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.
    Charatcharoenwitthaya P; Enders FB; Halling KC; Lindor KD
    Hepatology; 2008 Oct; 48(4):1106-17. PubMed ID: 18785620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
    La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
    World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
    Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
    BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategy for mucin-producing intrahepatic cholangiocarcinoma: value of percutaneous transhepatic biliary drainage and cholangioscopy.
    Sakamoto E; Hayakawa N; Kamiya J; Kondo S; Nagino M; Kanai M; Miyachi M; Uesaka K; Nimura Y
    World J Surg; 1999 Oct; 23(10):1038-43; discussion 1043-4. PubMed ID: 10512944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Hultcrantz R; Olsson R; Danielsson A; Järnerot G; Lööf L; Ryden BO; Wahren B; Broomé U
    J Hepatol; 1999 Apr; 30(4):669-73. PubMed ID: 10207809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
    Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H
    J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
    Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
    J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis.
    Kim YT; Byun JS; Kim J; Jang YH; Lee WJ; Ryu JK; Kim SW; Yoon YB; Kim CY
    Hepatogastroenterology; 2003; 50(49):8-12. PubMed ID: 12629979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
    Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
    Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
    Li YG; Zhang N
    Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
    Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
    Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristic Features of Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis.
    Ishii Y; Sasaki T; Serikawa M; Kobayashi K; Kamigaki M; Minami T; Okazaki A; Yukutake M; Ishigaki T; Kosaka K; Mouri T; Yoshimi S; Chayama K
    Hepatogastroenterology; 2014 May; 61(131):567-73. PubMed ID: 26176037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The value of CA19-9 and CEA in predicting resectability of hilar cholangiocarcinoma].
    Zong D; Zeng Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):819-22. PubMed ID: 25341348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraductal growth-type mucin-producing peripheral cholangiocarcinoma associated with biliary papillomatosis.
    Güllüoglu MG; Ozden I; Poyanli A; Cevikbas U; Ariogul O
    Ann Diagn Pathol; 2007 Feb; 11(1):34-8. PubMed ID: 17240305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor markers as a diagnostic key for hilar cholangiocarcinoma.
    Juntermanns B; Radunz S; Heuer M; Hertel S; Reis H; Neuhaus JP; Vernadakis S; Trarbach T; Paul A; Kaiser GM
    Eur J Med Res; 2010 Aug; 15(8):357-61. PubMed ID: 20947473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
    J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
    Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
    Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma.
    Esnaola NF; Meyer JE; Karachristos A; Maranki JL; Camp ER; Denlinger CS
    Cancer; 2016 May; 122(9):1349-69. PubMed ID: 26799932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.